BMI Genetic Predisposition and Your Genetics

Written by Scott Peeples, BS Biomedical Sciences | ExomeDNA Founder Reviewed by ExomeDNA Editorial Process

Body mass index measured in non-smoking populations provides a metabolic phenotype unconfounded by the appetite-suppressing and metabolic-rate effects of nicotine. Genome-wide association studies of BMI in non-smokers reveal a cleaner genetic architecture of weight regulation—and variants near BDNF and CADM2 emerge as key signals, pointing toward neurotrophic signaling in hypothalamic appetite circuits and synaptic connectivity in reward and satiety pathways as central determinants of BMI in tobacco-naive biology.

What is Body Mass Index in Non-Smokers?

Body mass index (BMI) measured within non-smoking populations allows researchers to identify genetic variants whose effects operate through metabolic pathways independent of nicotinic signaling. Nicotine suppresses appetite and elevates resting metabolic rate through activation of nicotinic acetylcholine receptors—effects that can mask or amplify other genetic signals when smokers are included in GWAS cohorts.

A non-smoker-stratified genome-wide analysis reveals the baseline genetic architecture of weight regulation as it operates in the absence of pharmacological tobacco effects. This stratification is methodologically important: it partitions the genetic architecture of BMI by the pharmacological context in which it expresses, revealing signals with cleaner mechanistic interpretation.

Research base: Robust

The genetics behind BMI in Non-Smokers

BDNF: neurotrophic regulation of hypothalamic appetite circuits

BDNF encodes brain-derived neurotrophic factor, a member of the neurotrophin family critical for neuronal survival, growth, and synaptic plasticity. In the context of metabolism, BDNF plays a specific role in hypothalamic circuits regulating energy intake and expenditure. Neurons in the ventromedial hypothalamus (VMH) express high levels of BDNF, and VMH-derived BDNF acts as a downstream effector of melanocortin signaling—the same pathway targeted by the well-characterized MC4R BMI locus.

BDNF signals through its primary receptor TrkB (encoded by NTRK2), activating intracellular pathways that promote neuronal health and appetite regulation. Reduced BDNF-TrkB signaling in hypothalamic circuits is associated with hyperphagia and increased adiposity in animal models. The BDNF Val66Met polymorphism (rs6265) is one of the most studied functional variants in metabolic and neuropsychiatric genetics—it affects activity-dependent BDNF secretion from neurons and has been associated with BMI variation in multiple cohorts.

BDNF-AS encodes a natural antisense long non-coding RNA transcribed from the BDNF locus in the opposite direction. BDNF-AS negatively regulates BDNF mRNA expression; variants affecting BDNF-AS function can therefore modulate BDNF protein levels and downstream hypothalamic appetite circuit tone.

CADM2: synaptic adhesion and reward-circuit connectivity

CADM2 (cell adhesion molecule 2) encodes a synaptic adhesion protein expressed widely in the brain, with particularly high expression in hypothalamic and prefrontal regions involved in appetite regulation and executive control of food intake. CADM2 mediates trans-synaptic cell adhesion, contributing to the organization of synaptic contacts and the maintenance of neural circuit architecture.

CADM2 has emerged as one of the most robust cross-phenotype signals in BMI genetics, appearing in GWAS of not only body weight but also educational attainment, risk tolerance, and impulsivity-related traits. This cross-phenotype architecture suggests that CADM2 variation affects broad neural circuit properties—including cognitive control of food intake, reward sensitivity to palatable foods, and the balance between impulsive eating and regulatory restraint—that collectively influence BMI.

The BMI non-smoker signal at the CADM2 locus, absent the confound of nicotinic appetite suppression, captures the gene's contribution through purely neural circuitry mechanisms.

Additional authorized genes

CALCR encodes the calcitonin receptor, a G protein-coupled receptor expressed in bone, kidney, and brain. In the hypothalamus, calcitonin receptor signaling contributes to energy homeostasis and has been linked to amylin-mediated satiety. ADCY3 (adenylyl cyclase 3), expressed in hypothalamic and olfactory neurons, generates cAMP in response to appetite-regulating hormones. ASTN2 (astrotactin 2) mediates neuronal migration and has appeared in neurological and metabolic phenotype GWAS. ATP2A1 encodes the SERCA1 calcium pump; calcium signaling in muscle and adipose tissue affects metabolic rate. ADPGK encodes ADP-dependent glucokinase, involved in cellular glucose sensing and energy metabolism.

Robust evidence classification The BDNF and CADM2 loci carry Robust confidence tier ratings—reflecting genome-wide significant associations, consistent effect direction across cohorts, and biological plausibility supported by independent functional evidence in hypothalamic neuroscience and synaptic biology. Robust classification distinguishes these signals from Moderate-tier loci that are replicated but less thoroughly annotated.

What the research says

The GWAS associated with PMID 28443625 applied a non-smoker-stratified analysis to a large BMI dataset, identifying genetic variants whose effects are detectable in populations free from nicotinic appetite confounds. This stratification approach reveals the baseline metabolic genetic architecture operating through purely biological weight-regulation mechanisms—making the signals at BDNF and CADM2 particularly interpretable in terms of non-pharmacological appetite biology.

Both BDNF and CADM2 are among the most biologically annotated BMI GWAS loci in the literature. BDNF's hypothalamic role in melanocortin-pathway appetite regulation is established across animal models, human imaging genetics studies, and rare-variant genetics (BDNF haploinsufficiency causes severe obesity in humans). CADM2's cross-trait architecture—appearing in BMI, educational attainment, and impulsivity studies—has been interpreted as evidence that neural circuit properties governing cognitive control of food intake are genetically co-regulated with other executive function traits.

CADM2 cross-phenotype depth CADM2 has been independently identified in GWAS of BMI, educational attainment, risk-taking behavior, and impulsivity. This cross-phenotype convergence on a synaptic adhesion molecule expressed in prefrontal-hypothalamic circuits is a strong indicator that CADM2 influences a core property of neural circuit architecture—one dimension of which is the cognitive regulation of food intake and appetite.

How BMI in Non-Smokers affects you

In non-smokers, BMI reflects the baseline genetic and environmental architecture of weight regulation without the modifying influence of nicotinic signaling. For individuals with variants at the BDNF and CADM2 loci, the underlying biology points to:

Hypothalamic appetite circuit tone: BDNF variants affect the efficiency of VMH-mediated appetite suppression downstream of melanocortin signaling. Individuals whose BDNF biology sits lower in the population distribution of hypothalamic BDNF activity may find that their homeostatic hunger signaling runs slightly warmer—a subtle but cumulative difference in appetite set-point.

Cognitive control of food intake: CADM2 variation affects the synaptic connectivity of circuits governing impulse control and reward sensitivity, including their application to food choices. This is not a deterministic effect on behavior; it is a polygenic contribution to the neural architecture that supports—or makes more effortful—deliberate, restrained eating patterns.

BDNF Val66Met and secretion efficiency: The functional Val66Met variant (rs6265) in the BDNF prodomain affects activity-dependent BDNF secretion from neurons. Met allele carriers show reduced activity-dependent secretion—meaning that in contexts requiring hypothalamic appetite control under metabolic demand, BDNF release may be less robust, contributing to a subtle shift in energy intake regulation.

The ExomeDNA score for this trait reflects the aggregate of GWAS-identified variants at these loci. A higher score associates with higher BMI in non-smoking population cohorts.

Working with your BMI in Non-Smokers profile

Exercise as BDNF upregulation: Aerobic exercise is one of the most reliable non-pharmacological inducers of BDNF expression in the brain, including in hypothalamic circuits. Consistent cardiovascular activity—at intensities that elevate heart rate for sustained periods—increases BDNF transcription and activity-dependent secretion, directly supporting the hypothalamic appetite circuit biology identified by this GWAS signal. This represents a direct mechanistic alignment between the genetic signal and an evidence-based lifestyle intervention.

Structured eating environments: Because CADM2 biology points to cognitive circuit architecture underlying food intake control, individuals with lower CADM2-driven circuit connectivity may benefit more from environmental structure—regular meal timing, pre-planned food environments, reduced exposure to high-palatability food cues—than from relying on in-the-moment restraint. Reducing the cognitive demand required for appetite control can compensate for genetic differences in circuit connectivity.

Protein and satiety: Dietary protein robustly elevates satiety hormones including GLP-1 and CCK, and reduces appetite acuity across the inter-meal interval. For individuals with lower hypothalamic BDNF-mediated appetite suppression, protein-forward dietary patterns can provide a peripheral satiety signal that supplements central circuit function.

Sleep and BDNF: Sleep is essential for BDNF expression in the brain. Chronic sleep restriction reduces BDNF levels in cortical and hypothalamic regions, compounding genetic predisposition toward lower hypothalamic BDNF tone. Prioritizing sleep quality and duration directly supports the biological pathway identified by this genetic signal.

Related traits and genes

• BMI in smokers (overlapping GWAS loci including BDNF, with a distinct genetic architecture shaped by nicotinic signaling)
• Waist-to-hip ratio (CADM2 appears in fat distribution GWAS as well as BMI GWAS)
• Educational attainment (CADM2 cross-phenotype signal well-replicated in social science GWAS)
• Impulsivity and risk tolerance (CADM2 cognitive circuit architecture)
• Calcitonin and bone metabolism (CALCR-mediated physiology connecting bone turnover and energy homeostasis)
• Resting metabolic rate (ADCY3 and cAMP signaling in energy homeostasis)

Frequently asked questions

Q: Why is BMI in non-smokers analyzed separately from the general population? A: Nicotine is a potent appetite suppressant and metabolic rate modifier. When smokers are included in BMI GWAS, their genetic signals are partly confounded by tobacco's pharmacological effects on weight-regulating biology. A non-smoker-stratified analysis reveals the baseline genetic architecture of BMI without this confounder, making signals at loci like BDNF and CADM2 cleaner and more interpretable in terms of biological mechanism.

Q: What is the BDNF Val66Met variant and does it appear in my ExomeDNA score? A: BDNF Val66Met (rs6265) is a functional variant in the BDNF prodomain that reduces activity-dependent secretion of mature BDNF protein from neurons. It is one of the most studied variants in both neuropsychiatric genetics and metabolic GWAS. Whether it is included in your ExomeDNA polygenic score depends on which variants passed quality control in your genotyping data and their inclusion in the GWAS summary statistics used for score construction.

Q: How does a synaptic adhesion molecule like CADM2 affect body weight? A: CADM2 organizes synaptic contacts in neural circuits including prefrontal-hypothalamic connections that govern cognitive control of appetite, reward responses to food, and the balance between impulsive and deliberate eating. Variation in this synaptic architecture contributes statistically to BMI differences across populations—not by making individuals incapable of self-regulation, but by shifting the neural efficiency of cognitive appetite regulation at the circuit level.

Q: Does this score apply if I am a former smoker or never-smoker? A: This GWAS was specifically conducted in non-smoking individuals, so the genetic associations are most interpretable for current non-smokers or never-smokers. Former smokers, especially those who quit years ago, likely align reasonably well with this non-smoker biology, though the transition period around cessation may temporarily alter how the genetics express in measured BMI.

Q: Can exercise compensate for lower BDNF activity from genetics? A: Aerobic exercise reliably upregulates BDNF expression and secretion in the brain, including hypothalamic regions relevant to appetite. This is not a complete override of genetic predisposition, but it is a meaningful modifier—exercise-induced BDNF elevation can supplement baseline BDNF activity in appetite circuits, supporting more effective hunger signaling and satiety perception over time.

Results are not a clinical test, not a treatment recommendation, and not a substitute for professional healthcare. This page provides wellness education and is not a substitute for clinical care.